Aberrant activation of AKT disturbs the proliferation, survival and metabolic homeostasis of various human cancers. Thus, it is critical to understand the upstream signalling pathways governing AKT activation. Here, we report that AKT undergoes SETDB1-mediated lysine methylation to promote its activation, which is antagonized by the Jumonji-family demethylase KDM4B. Notably, compared with wild-type mice, mice harbouring non-methylated mutant Akt1 not only exhibited reduced body size but were also less prone to carcinogen-induced skin tumours, in part due to reduced AKT activation. Mechanistically, the interaction of phosphatidylinositol (3,4,5)-trisphosphate with AKT facilitates its interaction with SETDB1 for subsequent AKT methylation, which in turn sustains AKT phosphorylation. Pathologically, genetic alterations, including SETDB1 amplification, aberrantly promote AKT methylation to facilitate its activation and oncogenic functions. Thus, AKT methylation is an important step, synergizing with PI3K signalling to control AKT activation. This suggests that targeting SETDB1 signalling could be a potential therapeutic strategy for combatting hyperactive AKT-driven cancers. NATuRE CELL BioLoGY | VOL 21 | FEBRUARY 2019 | 226-237 | www.nature.com/naturecellbiology 226 Articles NATurE CEll BIology AKT2 AKT3 AKT1 H. sapiens P. troglodytes M. mulatta B. taurus M. musculus R. norvegicus D. rerio X. tropicalis G. gallus H. sapiens 137 1 46 139 1 48 138 146 H. sapiens PH KD HM K140 K142 1 481 AKT1 g b WT K140/142R Soft agar a c d f Relative colony number HEK293 HEK293 Time (min) 2-NBDG uptake (%)
pigenetic regulation, such as DNA methylation and histone modifications, plays important roles in governing gene expression patterns during human development and disease progression 1, 2 . Inhibitors targeting epigenetic factors have been explored for cancer therapies and have undergone clinical trials, including DNA methyltransferase 1 inhibitors, histone deacetylase inhibitors and histone methyltransferase inhibitors [3] [4] [5] . Among these epigenetic inhibitors, those targeting histone methyltransferases (such as EZH2 and DOT1L) display impressive efficacy in patients with cancer 6, 7 . This robust efficacy may also be attributed to the regulation of the methylation of non-histone proteins such as Rb and p53, in addition to regulating histone methylation [8] [9] [10] [11] . However, it remains largely unknown whether predominant oncogenic signalling pathways that are frequently activated in human cancers, such as the PI3K-AKT signalling pathway, are subjected to methylationdependent regulation. Thus, the identification of the major oncogenic proteins governed by methylation is critical to identify new therapeutic targets.
Hyperactivation of PI3K-AKT signalling is a central module of cell proliferation, survival and metabolic homeostasis in human cancers 12, 13 . Physiologically, stimulations derived from various types of growth factors tend to activate AKT, which in turn phosphorylates distinct substrates to perform different biological processes 13, 14 .
Recently, emerging evidence has demonstrated that distinct signals govern AKT kinase activity. For example, the TRAF6-or SKP2mediated positive regulation of AKT in a ubiquitination-dependent manner 15 , the CDK2-cyclin A-mediated positive regulation of AKT in a tail phosphorylation-dependent manner 16 and the pVHLmediated negative regulation of AKT in a hydroxylation-dependent manner 17 . However, the regulation of AKT by histone methyltransferases as a non-histone substrate is not well defined.
Here, we show that AKT1 methylation in its linker region is mediated by the histone methyltransferase SETDB1, which is antagonized by the demethylase KDM4B. Biologically, the absence of AKT1 methylation attenuates its kinase activity, which in turn represses cell growth, glucose uptake and tumorigenesis. As a result, deficiency in AKT methylation can physiologically decrease mouse body size and can protect mice from developing carcinogeninduced skin tumours. Thus, our data unravel a profound role for the SETDB1-KDM4B axis in manipulating AKT activity and highlight the histone methyltransferase SETDB1 as a potential target for combating hyperactive AKT-driven tumours.
Results
Methylation of AKT enhances its kinase activity. To identify important non-histone proteins that are regulated in a methylationdependent manner, we used a specific pan-lysine trimethylation (Kme3) antibody and performed a mass spectrometry (MS)-based screening of cell lysates derived from ovarian cancer cells 10 (Fig. 1a ; Supplementary Fig. 1a ). Notably, an AKT1-derived peptide was identified, containing methylated modifications at two nearby evolutionarily conserved lysine residues (K140 and K142) in the AKT1 linker region ( Fig. 1b ; Supplementary Table 1 ). Furthermore, AKT1 methylation was validated using the Kme3-specific antibody in cells were proteolytically digested to perform IAP LC-MS/MS assays. b, Alignment of MS-characterized putative AKT1 methylation residues among different species, AKT2 and AKT3. PH, Pleckstrin homology domain; KD, kinase domain; HM, hydrophobic region. c, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from DLD1-AKT1/2 -/cells infected with indicated AKT1-encoding lentivirus (Lenti) or empty lentivirus (EV) and selected with hygromycin (200 μ g ml -1 ) for 72 h before collection. Data shown represent two independent experiments. d,e, Cells generated in c were subjected to colony-formation and soft agar assays. The experiments were performed twice independently with three repeats, and exhibited similar results (d). Representative images are shown in d, and relative colony numbers derived from two independent experiments are plotted in e. f-h, Cells generated in c were subjected to mouse xenograft assays. Tumour sizes were monitored (f), and dissected tumours were weighed (g,h) . Data in f and h represent the mean ± s.e.m., n = 7 mice. i,j, K140R and K142R mutations of AKT1 were genetically engineered in HEK293 cells using the CRISPR-Cas9-based technique. Resulting cells were serum-starved for 12 h and then collected for IB analysis at different time points after stimulation with insulin (100 nM) (i). The experiment was performed twice independently with similar results (i). Cells generated in i were assessed for proliferation assays (j). The experiment in j was performed three times independently, and exhibited similar results. Data in j represent the mean ± s.e.m., n = 3 independent experiments. k-m, Cells generated in i were subjected to colony formation (k), glucose uptake (l) and lactate production (m) assays. The experiments were performed twice independently with three repeats, and exhibited similar results (k-m). Relative colony numbers, glucose and lactate levels derived from two independent experiments are plotted in k-m. Two-way ANOVA was performed in f and j to calculate the P values. Detailed statistical tests are described in the Methods. Source data for e, f, h and j-m are shown in Supplementary Table 2 . Scanned images of unprocessed blots are shown in Supplementary Fig. 8 .
treated with a global histone methylation inhibitor, 3-deazaneplanocin A ( Supplementary Fig. 1b ). Additional MS analyses of ectopically expressed AKT1 further confirmed the trimethylation of K140 and K142, for which monomethylation and dimethylation events were also identified ( Supplementary Fig. 1c ). Moreover, K64, another lysine residue in the PH domain of AKT1, was identified to be monomethylated in our system. Interestingly, mutation of both K140 and K142 residues led to a dramatic reduction of AKT1 Kme3 signals in cells ( Supplementary Fig. 1d ), indicating that K140 and K142 might be the major AKT1 Kme3 residues. In addition, consistent with a previous report 18 , deletion of Smyd3, a gene that encodes a methyltransferase targeting MAP3K2, did not disturb AKT kinase activity in cells, even though an interaction of SMYD3 with AKT1 has been previously reported 19 ( Supplementary Fig. 1e -g). Given that both K140 and K142 sites were identified at endogenous levels through our large-scale non-biased MS approach, we chose to mainly focus on understanding the contribution of K140 and K142 trimethylation to AKT activity and oncogenic functions in the remainder of this study.
Absence of AKT methylation represses its oncogenic functions in cells and increases resistance to carcinogen-induced skin tumours in vivo.
To reveal the potential biological functions of trimethylation within its linker region of AKT1, a methylationdeficient variant of AKT1 (K140R and/or K142R) was ectopically expressed in DLD1 cells in which both AKT1 and AKT2 were knocked out (DLD1-AKT1/2 -/-). Compared to wild-type AKT1 (AKT1-WT), the AKT1-K140/142R mutant, and to a lesser extent, AKT1-K140R and AKT-K142R, exhibited significantly reduced activation. This was shown by a marked reduction in AKT-pT308 and AKT-pS473, as well as its downstream targets, pGSK3β and pFOXO3a ( Fig. 1c ; Supplementary Fig. 1h -j). This observation was associated with a reduction in AKT1 kinase activity, as observed in vitro ( Supplementary Fig. 1k ). As a consequence, absence of methylation on K140 and K142 led to reduced cell colony formation, anchorage-independent growth, glucose uptake and lactate production in vitro ( Fig. 1d ,e; Supplementary Fig. 1l ,m), and reduced tumour growth in vivo ( Fig. 1f-h ; Supplementary Fig. 1n ,o).
To explore the role of AKT methylation under physiological conditions, we generated AKT1-K140/142R double mutations in HEK293 cells (termed AKT1 K140/142R ) using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated protein-9) 20 technology ( Supplementary Fig. 1p-r) . Notably, the presence of the K140/142R mutations in endogenous AKT1 decreased AKT phosphorylation in response to various stimuli ( Fig. 1i ; Supplementary Fig. 1s -u), and also compromised cell growth, colony formation, glucose uptake and lactate production ( Fig. 1j-m ). Next, we generated mice in which the AKT1-K140/142R double mutation was knocked in (termed Akt1 KI/KI ) ( Supplementary Fig. 2a -c). Compared with the WT mice, Akt1 KI/KI mice exhibited a decrease in body size and weight ( Fig. 2a,b ; Supplementary Fig. 2d -f), organ size and weight ( Fig. 2c; Supplementary Fig. 2g ) and AKT kinase activity ( Fig. 2d ,e; Supplementary Fig. 2h ), phenocopying Akt1 -/mice 21 . To pinpoint whether methylation-deficient mutants of Akt1 abrogate tumorigenesis in vivo, we utilized a two-step chemical carcinogen (DMBA (7,12-dimethylbenzanthracene) followed by TPA (12-O-tetradecanoylphorbol-13-acetate))-induced skin tumour model 22 . In this model, we observed that Akt1 KI/KI mice displayed a lower incidence of skin tumours and reduced papilloma burden compared with WT mice (Fig. 2f-h ), which correlated with decreased AKT signalling ( Fig. 2i ). Together, these results support the notion that methylation of AKT in its linker region probably promotes AKT kinase activity and oncogenic functions both in vitro and in vivo.
SETDB1 methylates and activates AKT.
Next, we set out to identify the physiological upstream methyltransferase (or methyltransferases) for AKT. Consistent with previous reports [23] [24] [25] , we found that there was a relatively strong physical interaction between AKT1 and two trimethyltransferases, SETDB1 and EZH2 ( Fig. 3a ; Supplementary Fig. 2i ). Interestingly, genetic alterations of both SETDB1 and EZH2 tended to mutually exclude alterations in PI3K-AKT pathway-related genes, including PTEN deficiencies, EGFR, PIK3CA or AKT1 amplifications, or mutations in human melanoma and breast cancer 26 ( Supplementary Fig. 2j ). Furthermore, SETDB1, but not other methyltransferases, including EZH2, could enhance AKT trimethylation in cells ( Supplementary  Fig. 2i ). This result indicates that unlike EZH2, which is a downstream substrate of AKT 25 , SETDB1 may be an upstream regulator of AKT methylation ( Supplementary Fig. 2k ).
Notably, SETDB1 specifically interacted with the PH domain of AKT1 and, to a lesser extent, AKT2 and AKT3 ( Fig. 3b ; Supplementary Fig. 2l ,m). Interestingly, mutation of AKT1 methylated residues (K140/142R) markedly decreased the interaction of AKT1 with SETDB1 ( Supplementary Fig. 3a ). Importantly, the Tudor domain of SETDB1 was identified to bind AKT1, which was enhanced by enforcing the expression of WT, but not the SETDB1-H1224K catalytic inactive mutant ( Fig. 3c ; Supplementary Fig. 3b ).
These results indicate that SETDB1 could be a potential reader of the AKT1-K140/K142 methylation events through its Tudor domain. Furthermore, by enhancing its interaction with AKT1, SETDB1 promoted AKT1 methylation on additional residues (such as K64). In addition, SETDB1 promoted AKT1 trimethylation in an enzymatic activity-dependent manner in cells ( Fig. 3d ), and mutation of the K140 and/or K142 residue decreased SETDB1-mediated AKT1 trimethylation in cells ( Supplementary Fig. 3c ). Moreover, 3 H-S-adenosyl-methionine (SAM)-mediated in vitro methylation assays also indicated that SETDB1 could directly methylate AKT1 at the K140 and K142 residues ( Fig. 3e ). Hence, these results coherently support the notion that SETDB1 serves as a putative AKT1 methyltransferase. SETDB1 promotes cell growth and glycolysis through the methylation of AKT. As a histone H3 methyltransferase capable of catalysing trimethylation on K9 of histone H3 (H3K9me3) 27 , SETDB1 is amplified in various cancers [28] [29] [30] [31] . Notably, we identified that in addition to localizing in the nucleus and modifying histone marks, SETDB1 occurs in the cytoplasm of cells ( Supplementary  Fig. 3d ). To further elucidate the physiological functions attributed to methylated AKT1, we generated specific antibodies against trimethylation of AKT1 at K140 (termed K140me3), which was validated by dot blot and immunoprecipitation assays ( Supplementary  Fig. 3e ,f), and recognized SETDB1-mediated trimethylation of AKT1 at K140 in cells ( Fig. 3f ; Supplementary Fig. 3g ) and in vitro ( Fig. 3g ; Supplementary Fig. 3h ). Additionally, genetic depletion of SETDB1 markedly reduced AKT1-K140me3 in cells ( Fig. 3h -j; Supplementary Fig. 3i ). Compared with AKT1-WT, a cancer patient-derived AKT1-E17K mutant 32 displayed an enhanced interaction with SETDB1, coupled with an increase in its K140 methylation level ( Fig. 3k ; Supplementary Fig. 3j ,k). These findings suggest that AKT1 is a bona fide methylation substrate of SETDB1.
Importantly, genetic deletion of Setdb1 in cells diminished AKT activation ( Fig. 3i ,j,l; Supplementary Fig. 3l -o). Furthermore, depletion of endogenous SETDB1 by short hairpin RNA (shRNA) also reduced AKT-pT308 in different cancer cell lines ( Supplementary  Fig. 4a,b ), leading to suppression of colony formation, anchorageindependent growth and glucose uptake in cells ( Supplementary  Fig. 4c-f ). Conversely, ectopic expression of SETDB1-WT, but not SETDB1-H1224K 27 , induced AKT-pT308 in Setdb1-deficient mouse embryonic fibroblasts (MEFs) ( Fig. 3l ). Collectively, these results indicate that the activation of AKT by SETDB1 appears to be methylation-dependent. Of note, consistent with a previous report 28 , immunohistochemistry (IHC) staining revealed that compared to -week-old mice were weighed (comprising 15 male mice, with 5 WT, 5 heterogeneous (WT/KI) and 5 homogenous Akt1 K140/142R (KI/KI) genetic background status). Data represent the mean ± s.e.m., n = 5 mice. P values were calculated using two-tailed unpaired Student's t-test. c, The mice in b were killed and their organs were dissected and weighed. Data represent the mean ± s.e.m., n = 5 mice. P values were calculated using two-tailed unpaired Student's t-test. d, IB analysis of WCL derived from livers or hearts of WT, Akt1 K140/142R knock-in heterogeneous or homogenous mice from the same litter at the age of 4 weeks. The experiment was performed twice, independently, with similar results obtained. e, Representative images of H&E and IHC staining of heart and liver tissues derived from WT or Akt1 K140/142R knock-in mice. Scale bar, 50 μ m. This experiment was performed twice independently, with similar results obtained. f, Side view of 12-week-old mice derived from WT or Akt1 K140/142R knock-in mice treated with chemical carcinogen (DMBA followed by TPA). The neoplasm lesions are indicated by arrowheads. g,h, The tumour incidence (g) and lesion numbers (h) of the mice described in f were calculated and plotted. Data represent the mean ± s.e.m. (n = 16 mice for WT mice, n = 11 for Akt1 K140/142R mice). i, After 12 weeks of treatment with DMBA and TPA, the mice were killed, and H&E (left) and IHC staining (right) were performed. Scale bar, 1 mm. The experiment in was performed twice independently, with similar results obtained. Statistical source data for b, c, g and h are shown in Supplementary Table 2 . Scanned images of unprocessed blots are shown in Supplementary Fig. 8 . IB: AKT1 IgG was used as a negative control. e, In vitro methylation assays were performed with recombinant His-AKT1 proteins purified from insect cells as substrates and purified Flag-SETDB1 from HEK293T cells as the source of methyltransferase in the presence or absence of 3 H-SAM. g, In vitro methylation assays were performed with IP Flag-SETDB1 derived from HEK293T cells as the source of methyltransferase, and the synthetic AKT1 peptides containing K140 and K142 as the substrates. AKT1-K140me3 peptides were used as a positive control. i, IB analyses of IP products and WCL derived from A375 cells lentivirally transfected with shRNAs against SETDB1. Resulting cells were selected with puromycin for 72 h before collection. j, Setdb1 conditional knockout MEFs were treated with or without 4-OHT (4-hydroxytamoxifen, 500 nM) for 48 h to deplete endogenous Setdb1, then resulting cells were serum-starved for another 20 h and stimulated with insulin (100 nM) for 15 min before being collected and subjected to IP and IB analysis. k, IB analysis of IP products and WCL derived from HEK293 cells transfected with indicated constructs. l, Setdb1 conditional knockout MEFs were infected with WT or H1224K-SETDB1 encoding virus and selected with puromycin for 72 h, then treated with or without 4-OHT (500 nM) for another 48 h before collection for IB analyses. m-q, Images of the IHC staining for SETDB1, AKT-pS473 and AKT-K140me3 in a melanoma tissue microarray (m,o). Scale bar, 50 μ m. The distribution of SETDB1 staining is plotted in n (n = 97 tissue specimens). The correlation of AKT-pS473 or AKT-K140me3 with SETDB1 are plotted in p and q (n = 95 tissue specimens). Western blots in a-l were performed twice independently, with similar results obtained. P values were calculated using chi-squared tests in n-q. Statistical source data for n-q are shown in Supplementary Table 2 . Scanned images of unprocessed blots are shown in Supplementary Fig. 8 .
nevus tissues, SETDB1 is highly expressed in melanoma, especially in metastatic malignancies ( Fig. 3m,n) , and positively correlates with AKT1-K140me3 and AKT-pS473 IHC signals ( Fig. 3o-q ). SETDB1 is suggested to accelerate melanoma onset in cooperation with BRAF V600E (ref. 28 ). Given that coordinated actions of BRAF V600E with activated AKT are required to promote melanomagenesis 33, 34 , we employed a well-established human immortalized melanocyte (HIM) model 35 to examine whether SETDB1 modulates the activation of AKT. To this end, we found that concomitant activation of AKT and ERK signalling by SETDB1 and BRAF V600E led to a marked enhancement of anchorage-independent cell growth, coupled with increased AKT phosphorylation ( Fig. 4a-c ). Furthermore, deletion of endogenous AKT1 in HEK293 cells compromised the oncogenic capability of SETDB1 to promote cell colony formation compared with parental cells (Fig. 4d-f ).
More importantly, depletion of SETDB1 resulted in decreased AKT phosphorylation and cellular malignant phenotypes in AKT1-WTexpressing DLD1-AKT1/2 -/cells, but did not in AKT1-K140/142Rexpressing cells that already displayed relatively lower oncogenic capacity than WT cells ( Fig. 4g-j) . These results indicate that AKT is probably one of the major downstream pathways through which SETDB1 exerts its oncogenic role. Consistently, re-introduction of constitutively active AKT1 (myr-AKT1) partially restored the colony formation capability of SETDB1-depleted A375 cells ( Supplementary  Fig. 4g ,h). Furthermore, SETDB1 was capable of accelerating cell growth and colony formation in AKT1 WT , but not in the methylationdeficient AKT1 K140/142R -expressing HEK293 cells ( Fig. 4k -n). Hence, our results suggest that SETDB1 may exert its oncogenic roles largely through AKT activation in a methylation-dependent manner.
SETDB1-mediated AKT methylation crosstalks with PI3Kmediated AKT phosphorylation.
It is well established that AKT activation requires the PI3K-dependent generation of phosphatidylinositol (3,4,5)-trisphosphate (PtdIIns(3,4,5)P 3 ), which binds to the PH motif of AKT at the plasma membrane [36] [37] [38] . We explored the temporal relationship between methylation-dependent and PI3Kdependent activation of AKT in cells. We found that the interaction between AKT1 and SETDB1, and subsequent methylation of AKT, temporally coincided with AKT-pT308 following insulin or insulin-like growth factor (IGF) stimulation ( Fig. 5a ; Supplementary  Fig. 4i -k). Interestingly, PI3K inhibitors, but not AKT1 mutated variants (T308A and/or S473A), diminished the interaction of AKT1 with SETDB1 and decreased AKT1-K140 methylation in cells ( Fig. 5b ; Supplementary Fig. 4l ,m). This indicates that the PI3K pathway may function upstream of SETDB1-mediated AKT methylation to govern AKT activation. In further support of this notion, the non-PtdIns(3,4,5)P 3 binding mutation of AKT1-R25C 39 largely impaired the interaction between AKT and SETDB1, leading to a marked decrease in AKT1-K140 methylation (Fig. 5c,d) .
To further pinpoint the potential role of PtdIns(3,4,5)P 3 in mediating the interaction between SETDB1 and the PH motif of AKT1, we performed in vitro binding assays. The results showed that the interaction of SETDB1 with AKT1-WT, but not AKT1-R25C, was enhanced by PtdIns(3,4,5)P 3 in vitro ( Fig. 5e ; Supplementary  Fig. 5a -e), indicating that PIP 3 binding could induce a conformation change in the PH motif, which facilitates AKT1 binding to SETDB1. Importantly, PTEN deficiency dramatically increased AKT1-K140 methylation coupled with increased AKT-pT308 ( Supplementary  Fig. 5f ). Together, these data suggest that SETDB1 probably mediates AKT methylation in a PI3K catalytic activity-dependent manner.
Consistent with the finding that methylation of AKT1 could promote AKT-pT308, we observed that WT, but not the catalytically inactive SETDB1-H1224K, induced the interaction of AKT1 with PDK1 in cells ( Fig. 5f; Supplementary Fig. 5g ). Moreover, the methylation-deficient AKT1 mutant (K140/142R) or depletion of SETDB1 displayed an attenuated interaction with PDK1 compared with AKT1-WT ( Fig. 5g,h; Supplementary Fig. 5h ). In further support of the role for AKT methylation in controlling its activation, reducing AKT methylation by deleting Setdb1 or introducing the AKT1-K140/142R mutation diminished the interaction of AKT1 with PtdIns(3,4,5)P 3 (Fig. 5i,j) , and subsequently led to a marked decrease in the association of AKT1 with the cell membrane ( Fig. 5k,l ; Supplementary Fig. 5i-m) . These results indicate that methylated AKT1 may have a greater propensity to bind PtdIns(3,4,5)P 3 and translocate to the cellular membrane to achieve full activation. Thus, there is probably an intrinsic interplay between PI3K-mediated and SETDB1-mediated pathways to tightly control the spatial and temporal activation of AKT ( Supplementary Fig. 5n) .
Given that TRAF6-mediated AKT ubiquitination has a critical role in regulating AKT membrane translocation 15, 40, 41 , we also found that WT, but not the SETDB1-H1224K mutant, increased the interaction between AKT1 and TRAF6 ( Supplementary Fig. 5o) , resulting in increased AKT ubiquitination ( Supplementary Fig. 5p ). Furthermore, compared with AKT1-WT, AKT1-K140/142R displayed a reduced interaction with TRAF6 ( Supplementary Fig. 5q ), resulting in decreased AKT ubiquitination ( Supplementary Fig. 5r ). These findings suggest that SETDB1-induced methylation probably mediates the interaction of AKT1 with TRAF6, and subsequent AKT ubiquitination may promote the membrane translocation of methylated AKT ( Supplementary Fig. 5n ).
KDM4B demethylates and attenuates AKT kinase activity.
Importantly, the Jumonji 2 (JMJD2, also termed KDM4) family of proteins have been shown to function as specific erasers of SETDB1mediated H3K9me3 42 ; therefore, we assessed their ability to demethylate AKT1-K140me3. Notably, among all members of the KDM4 family, KDM4A and KDM4B, and to a lesser extent KDM4C, were observed to interact with AKT1 ( Fig. 6a; Supplementary Fig. 6a ). Furthermore, in vitro demethylation assays 42 demonstrated that KDM4B-WT, but not the catalytically inactive KDM4B-H189A or other KDM4 members, could efficiently erase the trimethylation of AKT1 at K140 in vitro ( Fig. 6b; Supplementary Fig. 6b-e ) and in cells ( Supplementary Fig. 6f ). Moreover, the interaction between KDM4B and AKT1 was readily induced by enforcing the expression of SETDB1-WT, but not its catalytic mutant (Fig. 6c ). We further found that AKT1 interacts with KDM4B through its Tudor domain ( Supplementary Fig. 6g -j) in a methylation-dependent manner ( Fig. 6d,e ; Supplementary Fig. 6k,l) . Hence, these data indicate that KDM4B might be a bona fide demethylase of AKT1.
KDM4B depletion concomitantly increased AKT-pT308 and K140me3 in multiple cell lines with AKT1-WT, but not in AKT1 K140/142R cells ( Fig. 6f-h ; Supplementary Fig. 6m-p) . Strikingly, depletion of KDM4A led to a reduction in AKT phosphorylation levels ( Supplementary Fig. 6q,r) . In addition, depletion of KDM4B, but not KDM4A, largely enhanced AKT1 membrane translocation ( Fig. 6i; Supplementary Fig. 6s ). Furthermore, the interaction between AKT1 and KDM4B primarily occurred in the later phase of insulin stimulation ( Supplementary Fig. 6t ). This interaction was abolished by PI3K inhibitors (Fig. 6j) . Consistent with the finding that KDM4B interacts with methylated AKT, the patient-derived mutation (AKT1-E17K) increased the interaction between AKT1 and KDM4B, while the non-PtdIns(3,4,5)P 3 binding mutation (AKT1-R25C) had the opposite effect (Fig. 6k ). Clinically, KDM4B was expressed at relatively high levels in benign nevus compared to malignant melanoma (Fig. 6l,m) . This observation correlated with decreased AKT-pS473 and K140me3 IHC signals (Fig. 6l,n,o) . Taken together, these data suggest that KDM4B might function as a negative regulator, antagonizing SETDB1-mediated methylation and activation of AKT.
SETDB1 is a potential therapeutic target of AKT-driven cancers. Given the critical role for the PI3K-AKT pathway in facilitating Resulting cells were subjected to soft agar assays (b,c). d, IB analysis of CRISPR-Cas9-mediated AKT1 knockout and parental HEK293 cells that were lentivirally infected with the constructs encoding SETDB1. e,f, Cells described in d were subjected to colony-formation assays. g-j, DLD1-AKT1/2 -/cells were infected with virus encoding WT or mutated AKT1, and selected with hygromycin for 72 h. Resulting cells were lentivirally infected with shRNA against SETDB1 (with shCtr as a negative control) and selected with puromycin for 72 h. Cells were then collected for IB analysis (g), cell proliferation (h), colony-formation and soft agar (i,j) assays. k-n, AKT1 K140/142R -edited and parental HEK293 cells were lentivirally infected with SETDB1-WT or SETDB1-H1224K (SETDB1-HK) encoding constructs and selected with puromycin for 72 h before collection for IB analyses (k). Resulting cells were subjected to proliferation (l) and colony formation (m,n) assays. The experiments in b, e, i and m were performed twice independently with three repeats, and exhibited similar results. Relative colony numbers derived from two independent experiments are plotted in c, f, j and n. The cell proliferation assays in h and l were performed three times independently, and cell numbers were quantified in h and l. Data represent the mean ± s.e.m., n = 3 independent experiments. Two-way ANOVA was performed in h and l to calculate the P values. Detailed statistical tests are described in the Methods. Source data for c, f, h, j, l and n are shown in Supplementary Table 2 . Western-blots in a, g and k were performed twice independently, with similar results obtained. Scanned images of unprocessed blots are shown in Supplementary Fig. 8 .
tumorigenesis, targeting hyperactive PI3K-AKT signalling via PI3K and/or AKT inhibitors has been pursued as a promising anticancer therapeutic approach. However, relatively high doses of these inhibitors induces cellular toxicity, restricting their potential use as a treatment option in patients with cancer 43, 44 . Thus, our finding that SETDB1 synergizes with PI3K to activate AKT kinase ( Supplementary  Fig. 7a ) indicates that SETDB1-specific inhibitors could benefit patients with cancer by targeting both H3K9-mediated epigenetic and PI3K-AKT oncogenic pathways. In support of this hypothesis, we found that depletion of SETDB1 significantly decreased A375 tumour growth in vivo ( Fig. 7a-d) , which was coupled with a reduction in H3K9me3 and AKT phosphorylation (Fig. 7e ). Consistent with a previous report 45 , we found that mithramycin A, an antineoplastic antibiotic, markedly decreased SETDB1 expression and H3K9me3 in different cells. Mithramycin A subsequently led to reduced AKT methylation and phosphorylation ( Fig. 7f ; Supplementary Fig. 7b ) and decreased the interaction between AKT1 and PDK1 (Fig. 7g ). Biologically, mithramycin A attenuated the phosphorylation and colony formation of cells expressing AKT1-WT, but not in AKT1/2-depleted DLD1 cells or AKT1 K140/142R -edited HEK293 cells ( Fig. 7h-j; Supplementary Fig. 7c-e ). To explore the potential antitumour roles of mithramycin A in vivo, we treated nude mice bearing A375 or DLD1 xenografted tumours, and found that mithramycin A significantly decreased tumour growth compared with the vehicle treatment ( Fig. 7k-n; Supplementary Fig. 7f-i) . Conceivably, the reduction of SETDB1 expression mediated by mithramycin A decreased H3K9me3 and AKT phosphorylation ( Supplementary  Fig. 7j ). Taken together, these results suggest that SETDB1 inhibition Resulting cells were serum starved for 20 h, then stimulated with IGF (100 ng ml -1 ) before collection for IP and IB analyses. h, IB analysis of IP products and WCL derived from A375 cells infected with lentivirus against KDM4B. i, IB analysis of cell fractionations separated from A375 cells lentivirally infected with shRNA against KDM4B or KDM4A. j,k, HEK293 cells were transfected with indicated constructs and treated with different PI3K inhibitors or dimethylsulfoxide (DMSO) for 1 h (j) before being subjected to GST pull-down assay and IB analyses. l-o, IHC staining of KDM4B, AKT1-pS473 and AKT1-K140me3 in a melanoma tissue microarray (l). Scale bar, 50 μ m. The distribution of KDM4B staining is plotted in m (n = 97 tissue specimens). The correlations of AKT1-pS473 or AKT1-K140me3 with KDM4B are plotted in n (n = 96 tissue specimens; o, n = 95 tissue specimens). All P values were calculated using chi-squared tests. Detailed statistical tests are described in the Methods. Western blots were performed twice independently, with similar results obtained. Statistical source data for m and n are shown in Supplementary Table 2 . Scanned images of unprocessed blots are shown in Supplementary Fig. 8 . Fig. 7 | Deficiency of SETDB1 inhibits AKT kinase activity and oncogenic function. a-d, SETDB1 -depleted A375 and control cells were subjected to mouse xenograft assays. Tumour sizes were monitored (a,b). Tumours were dissected (c) and tumour mass were weighed (d). Data represent the mean ± s.e.m., n = 7 mice. P values were calculated using two-way ANOVA (b) and two-tailed unpaired Student's t-test (d). e, The phosphorylation status of AKT1 (AKT-pT308) and methylation of H3K9 (H3K9me3) were detected by IB analysis with WCL derived from recovered xenografted tumours. f, IB analysis of IP products and WCL derived from A375 cells treated with different doses of mithramycin A for 72 h before collection. g, HEK293 cells were transfected with indicated constructs and treated with different doses of mithramycin A for 72 h before collection for GST pull-down assays and IB analysis. h-j, AKT1 K140/142R -edited and parental HEK293 cells were treated with different doses of mithramycin A for 72 h and subjected to IB analysis (h). The resulting cells were subjected to colony-formation (i) assay. The experiment was performed twice independently with three repeats, and exhibited similar results (i). Representative images are shown in i and relative colony numbers normalized with untreated cells derived from two independent experiments are plotted in j. k-n, Mithramycin A treatment reduced in vivo tumorigenesis of xenografted A375 cells. When the tumours of xenografted A375 cells reached 100 mm 3 , the mice were treated with mithramycin A (0.2 mg per kg) or PBS (as a negative control). Tumour sizes were monitored (k,l) and tumour mass were weighed (m,n). Data represent the mean ± s.e.m., n = 8 mice. P values were calculated using two-way ANOVA (l) and two-tailed unpaired Student's t-tests (n). Detailed statistical tests are described in the Methods. Source data for b, d, j, l and n are shown in Supplementary Table 2 . Scanned images of unprocessed blots are shown in Supplementary Fig. 8 .
could benefit patients with cancer by repressing AKT oncogenic signalling in addition to its well-characterized role in reprogramming the epigenome ( Supplementary Fig. 7k ).
Discussion
To identify novel non-histone methylated proteins involved in oncogenic signalling pathways, we performed a MS-based highthroughput screen and detected numerous proteins modified by lysine trimethylation. We showed that AKT1 could be methylated in its linker region, which was enhanced during physiological conditions such as growth factor (insulin or IGF) stimuli or pathological conditions, such as the AKT1-E17K mutation or PTEN deficiency. Absence of AKT methylation repressed its kinase activity and markedly decreased cell growth, glucose uptake and tumorigenesis. More strikingly, methylation-deficient Akt1 knock-in mice exhibited decreased body weight and size, which phenocopied Akt1 knockout mice 46 . Importantly, we also observed that methylation-deficient Akt1 knock-in could attenuate tumorigenesis in a carcinogen-induced skin tumour mouse model. Further investigations will be needed to determine whether knock-in methylation-deficient Akt1 in genetic alteration models, such as KRas G12D mutation and p53 depletionmediated lung cancer models (KP mice) 47 , could efficiently compromise lung tumorigenesis through decreased AKT activity.
Among the known upstream signals, AKT1-pT308 mediated by PDK1 is pivotal for AKT activation in a PtdIns(3,4,5)P 3 -dependent fashion 48 . Here, we observed that SETDB1-mediated AKT methylation crosstalks with PI3K-mediated AKT phosphorylation. We suspect that the binding of PtdIns(3,4,5)P 3 to the PH domain of AKT could 'unlock' the AKT autoinhibition conformation. This conformation change could be necessary for SETDB1 to interact with the AKT PH domain and to methylate AKT in its exposed linker region, in turn enhancing the interaction of AKT with its upstream kinase PDK1 ( Supplementary  Fig. 5n ). We also observed that SETDB1 enhanced the interaction of AKT with TRAF6 to facilitate AKT ubiquitination, subsequent PtdIns(3,4,5)P 3 binding and membrane translocation ( Supplementary  Fig. 5n ). Our model suggests a loop of AKT activation triggered by PtdIns(3,4,5)P 3 accumulation or the AKT1-E17K mutation, which could be antagonized by the demethylase KDM4B ( Supplementary  Fig. 5n ). Additionally, the SETDB1 Tudor domain interacts with AKT1 mainly in the context of the AKT1 linker region being methylated. Thus, we speculate that methylation of the linker region could be the primary modification that enhances the interaction of SETDB1 with AKT1, and sequentially promotes the methylation of AKT on other lysine residues (such as K64 in the PH domain of AKT). Consistent with our findings, another group also revealed that SETDB1-mediated AKT1 trimethylation at K64 plays an important role in AKT interacting with and being ubiquitinated by TRAF6 to facilitate AKT membrane translocation and kinase activation 49 . Therefore, the complicated connection and crosstalk of the SETDB1-mediated methylation of different lysine residues on AKT, including K140/K142 in the linker domain and K64 in the PH domain, warrants further investigation.
Finally, our study revealed that SETDB1 accelerates tumorigenesis largely through AKT activation in a methylation-dependent manner. As such, the function of SETDB1 is not restricted to the nucleus to repress gene transcription; SETDB1 also methylates non-histone proteins in the cytoplasm, such as AKT, to activate its oncogenic functions.
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Methods
Cell culture, transfection and cell fractionations. Cell line sources are detailed in the Reporting Summary. All cell lines were free of mycoplasma contamination (tested by the vendor). HEK293, HEK293T, DLD1, OVCAR5 and A375 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS), 100 units of penicillin and 100 μ g ml -1 streptomycin. HCT116 PTEN +/+ and PTEN -/cells were gifts from T. Waldman (School of Medicine, Georgetown University). Setdb1 f/f -ER-Cre MEFs were gifts from Y. Shinakai and M. C. Lorincz 50 . DLD1-AKT1/2 -/and counterpart cells were provided by B. Vogelstein (Johns Hopkins University School of Medicine), and these cells were maintained in DMEM supplemented with 10% FBS. HIM cells were cultured in keratinocyte serumfree medium (Gibco Life Technologies), supplemented with epidermal growth factor (EGF; 5 ng ml -1 ) and bovine pituitary extract (40 pg ml -1 ). Cell transfection was performed using Lipofectamine and Plus reagents, as described previously 17 . Packaging of lentiviral shRNA-or complimentary DNA (cDNA)-expressing viruses and retroviral cDNA-expressing viruses, as well as subsequent infection of various cell lines, were performed according to previously described protocols 17 . Following viral infection, cells were maintained in the presence of hygromycin (200 μ g ml -1 ) or puromycin (1 μ g ml -1 ) depending on the viral vectors used to infect cells.
To prepare primary MEFs, Jmjd2b flox/flox mice were crossed, and fibroblasts were established from embryonic day 13.5 embryos according to standard procedures. In brief, the embryos were dissociated and then trypsinized to produce single-cell suspensions. The cells were maintained in DMEM supplemented with 10% fetal calf serum (FCS), L-glutamine and antibiotics. The cells were infected with phage-Cre lentiviruses for 2 days to delete Jmjd2b. Kras;p53 and Kras;p53;Smyd3 -/cells derived from mouse lung and pancreas were obtained from P. K. Mazur (Stanford University School of Medicine) 18 .
Cell fractionations were performed using a Cell Fractionation kit (Cell Signaling Technology, 9038). The kinase inhibitors wortmannin (Selleck, S2758), BKM120 (Selleck, S2247) and LY294002 (Selleck, S1105) were used at the indicated doses. Mithramycin A (Sigma, M6891), growth factors, including EGF (Sigma, E9644), insulin (Invitrogen, 41400-045) and IGF (Sigma, SRP3069), were used at the indicated doses. PtdIns(3,4,5)P 3 beads (P-B00Ss) and free PtdIns(3,4,5)P 3 (P-3908) were purchased from Echelon Biosciences.
Plasmid construction. Constructs of pcDNA3-HA-AKT1, pcDNA3-HA-AKT2, pcDNA3-HA-AKT3 and pcDNA3-HA-myr-AKT1, pcDNA3-HA-AKT1-E17K, pET-GSK3β and pCMV-Flag-PDK1 were produced as previously described 17 Various AKT1 and KDM4B mutants were generated using a QuikChange XL Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's instructions. All mutants were generated using mutagenesis PCR, and the sequences were verified by DNA sequencing. sh-Akt1-resistant mutants were generated with specific primers as previously described 16 .
Antibodies. All antibodies were used at a 1:1,000 dilution in TBST buffer with 5% non-fat milk for western blotting. Anti-phospho-Ser473-AKT antibody (4060), antiphospho-Thr308-AKT antibody (2965), anti-AKT1 antibody (2938), anti-AKT total antibody (4691), anti-PDK1 antibody (13037), anti-SMYD3 antibody (12859), anti-H3K9me3 antibody (13969), anti-pan-Kme3 antibody (14680), anti-AIF (apoptosisinducing factor) antibody (5318), anti-histone H3 antibody (4499), anti-H3K4me2 antibody (9725), anti-phospho-Ser9-GSK3β antibody (5558), anti-GSK3β antibody (12456), anti-phospho-FOXO1 (Thr24)/FOXO3A (Thr32) antibody (9464), anti-FOXO3A antibody (2497), anti-GST antibody (2625), anti-pS6K1 (Thr389) antibody (9205), anti-S6K1 antibody (2708) and anti-pS240/244-S6 antibody (5364) were obtained from Cell Signaling Technology. Anti-SETDB1 antibody (11231) was obtained from Proteintech. Anti-KDM4A (A300-860A) and anti-KDM4B (A301-478A) antibodies were purchased from Bethyl. Anti-AKT1 agarose beads (sc-5298) and polyclonal anti-haemagglutinin (HA) antibody (sc-805) were obtained from Santa Cruz Biotechnology. Polyclonal anti-Flag antibody (F-2425), monoclonal anti-Flag antibody (F-3165, clone M2), anti-tubulin antibody (T-5168), anti-Flag agarose beads (A-2220), anti-HA agarose beads (A-2095), peroxidase-conjugated anti-mouse secondary antibody (A-4416) and peroxidase-conjugated anti-rabbit secondary antibody (A-4914) were obtained from Sigma. Monoclonal anti-HA antibody (MMS-101P) was obtained from Covance.
The polyclonal AKT1-K140me3 antibodies generated by Cell Signaling Technology were derived from rabbits, with each hydroxylation residue producing four clones. The antigen sequence used for immunization was AKT1 aa130-152 (GAEEMEVSLAKPKHRVTMNEFEY). K represents the trimethylation residue in this synthetic peptide. The antibodies were affinity purified using an antigen peptide column, but they were not counter-selected on unmodified antigen.
shRNAs, sgRNAs and CRISPR-Cas9-mediated knock-in and knockout assays.
shRNAs against SETDB1 were gifts from H. P. Koeffler 52 , and shRNAs against KDM4A were gifts from C. Wang 53 . shRNAs against KDM4B were reported previously 20, 54 .
The lentiviruses for CRISPR-Cas9-based editing of AKT1 were generated by cloning the annealed single guide RNAs (sgRNAs) into BsmBI-digested lentiCRISPR V2 vector, which encodes both Cas9 and an sgRNA of interest, as previously described 20 . The sgRNAs were designed using a CRISPR Design tool (crispr.mit.edu) and are as follows: sghAKT1 no.1 Forward: 5′ -CACCGTGAAGAGATGGAGGTGTCCC-3′ ; Reverse: 5′ -AAACGGGA CACCTCCATCTCTTCAG-3′ ; sghAKT1 no.2 Forward: 5′ -CACCGTGGGGA CAGGCCTCACCACG-3′ ; Reverse: 5′ -AAACCGTGGTGAGGCCT GTCCCCAC-3′ .
For knock-in experiments, the lentiCRISPR V2 constructs containing sgRNA (as mentioned above) were co-transfected with template DNA into HEK293 cells. After selected with puromycin for 2 days, resulting cells were seeded into 96-well plates with 1 cell per well. After culture for ~2 weeks, the single clone was expanded to a 12-well plate, at the same time, the genomic DNA of each clone was collected using DNA Extract Solution (Epicentre), and PCR was performed with primers that covered the guide RNA sequence (~600 bp). The PCR products were digested with SacII, which can digest the knock-in genome but not the WT AKT1 genome. The genomic DNAs of the digested clone were then subjected to sequencing to confirm the knock-in sequence. The examined clones were expanded and prepared for further studies.
The AKT-K140/142R guide DNA sequence is as follows: G GA GA TG GA CT TC CG GT CG GG CT CA CC CA GT GA CA AC TC AG GG GC-TG AA GA GA TG GA GG TG TC CC T C GC C AG GC CG CG G CA T C GC GT GG TG AG-GC CT GTCCCCACTTCTGCCTGTGCCTGGGGCTGCCTTGGACTGTGGAGG GCTGGGTG (the bold text indicates mutant nucleotides that restore K140/142 to R140/142, and at the same time generate a new Sac II digest site. The underlined nucleotides indicate the destruction of the sgRNA recognition site).
Generation and validation of Akt1 K140/142R knock-in mice. sgRNAs were synthesized using the in vitro transcription method (PNA Bio Company) with the following sequences: TGAAGAGATGGAGGTGTCCC and TGTGGTGAGTCTGGGCTCTG. Cas9 enzyme protein was obtained from PNA Bio. Mutated mouse genomic single strand template DNA (ssODN) was synthesized by Integrated DNA Technologies using the following s eq ue nce: G GA-CT CA AG AG GC AG GA AG AA GA GA CG AT GG AC TT CC GA TC AG GC TC AC CC-AG TG AC AA CT CA GG GG CT GAAGAGATGGAGGTGTCCCTCGCCAGGCCGC G G CATCGTGTGGTGAGTCTGGGCTCTGCTTCTGCTGGGGCTGCCAGGGG TTGTGGAGGGACCTGGTAGGTCCTGGTATTCCTGCCTGGCTTCCTGTAT GG (the bold text indicates mutant nucleotides that restore K140/142 to R140/142, and at the same time generate a new Sac II digest site. The underlined nucleotides indicate the destruction of the sgRNA recognition site). The mixture of Cas9 protein (200 ng μ l -1 ), sgRNA(s) (100 ng μ l -1 ) and ssODN DNA (10-70 ng μ l -1 ) in 50 μ l was utilized for generating knock-in mice by the transgenic facility at the Beth Israel Deaconess Medical Center.
The genomic DNAs derived from the tail of edited mice were extracted using QuickExtract DNA extraction solution (Epicentre, QE09050), and PCR was performed with the following primers: 5-AGGCCCAGGATCTGAGTGG (mAkt1geno-5′ ) and 5-TCAGCGGGCATCTTCATATTAC (mAkt1-geno-3′ ). The PCR products were digested with Sac II for 1 h or subjected to Sanger sequencing with the primer 5-GACAAGCACTCTGCCAACTG (mAkt1-seq-3′ ). The validated heterogeneous knock-in mice (termed founder mice, P1) were selected and crossed to each other, and WT, heterogeneous and homogenous Akt1 K140/142R knock-in mice were obtained (termed P2). Furthermore, we crossed homogenous knock-in mice with WT C57BL6 mice (Jackson Laboratories) and obtained the heterogeneous Akt1 K140/142R knock-in mice (termed P3). Then we crossed these heterogeneous knock-in mice to each other and obtained WT, heterogeneous and homogenous knock-in mice (termed P4). At this time point, we monitored the body size, organ size as well as AKT signalling among WT, heterogeneous and homogenous Akt1 K140/142R knock-in mice. To further diminish the nonspecific effect of genomic editing, we crossed back the homogenous knock-in mice (P4) with WT C57BL6 mice again to generate heterogeneous knock-in mice (P5) for further crossing and phenotype monitoring.
All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC, RN150D) at the Beth Israel Deaconess Medical Center (protocol no. 043-2015). The research projects that are approved by the IACUC are operated according to the applicable institutional regulations. The Institute is committed to the highest ethical standards of care for animals used for the purpose of continued progress in the field of human cancer research. IAP (Immunoaffinity purification)-LC-MS/MS screening. The experiments were performed as previously reported 10 . Briefly, OVCAR5 cell lysates were nature research | reporting summary April 2018 study have been deposited in ProteomeXchange under the accession code PXD011657 and are available to the public. All other data supporting the findings of this study are available from the corresponding author on reasonable request.
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Sample size
No sample size calculations were performed. Sample size was determined according to our experience as well as literature reporting in terms of specific experiment.
Data exclusions No samples or animals were excluded from the analyses

Replication
Multiple independent repeats were included for related experiments. Each experiment was performed for at least twice to make sure similar results are reproducible. Animal-related experiments and mass spectrometry experiments have been done once.
Randomization [6] [7] [8] week female nude mice were chosen as xenograft hosts. 10 days female and male WT and AKT1-K140/142R-Knockin mice were chosen to monitor the body weight. 4 weeks female and male WT and AKT1-K140/142R-Knockin mice were chosen for carcinogen treatment. All these mice were randomly allocated into experimental groups.
Blinding
For cell-based experiments Western blotting, immunostaining and FACS, cell types were known when prepare the samples or start to treat cells at the beginning of experiments. Data measurement for cell number and colony formation and soft agar assays were blinded to different person who processed assay at the time. IHC staining analysis were performed and analyzed blindedly.
Reporting for specific materials, systems and methods The polyclonal Akt1-K140-me3 antibodies generated by Cell Signaling Technology (CTS) were derived from rabbit, with each hydroxylation residue produced four clones. The antigen sequence used for immunization was Akt1 aa130-152 (GAEEMEVSLAKPKHRVTMNEFEY). K stands for tri-methylation residue in this synthetic peptide. The antibodies were affinity
